Marked increase in proton pump inhibitors use in Australia
- 8 July 2010
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 19 (10) , 1019-1024
Abstract
Objectives: To examine the trends in the prescribing of subsidised proton pump inhibitors (PPIs) and histamine receptor antagonists (H2RAs), in the Australian population from 1995 to 2006 to encourage discussion regarding appropriate clinical use. PPIs and H2RAs are the second highest drug cost to the publicly subsidised Pharmaceutical Benefits Scheme (PBS).Design: Government data on numbers of subsidised scripts, quantity and doses for PPIs and H2RAs were analysed by gender and age, dose and indication.Main outcome measure: Drug utilisation as DDD [defined daily dose]/1000 population/day.Results: The use of combined PPIs increased by 1318%. Utilisation increased substantially after the relaxation of the subsidised indications for PPIs in 2001. Omeprazole had the largest market share but was substituted by its S‐enantiomer esomeprazole after its introduction in 2002. There was considerable use in the elderly with the peak use being in those aged 80 years and over. The utilisation of H2RAs declined 72% over 12 years.Conclusions: PPI use has increased substantially, not only due to substitution of H2RAs but to expansion in the overall market. Utilisation does not appear to be commensurate with prevalence of gastro‐oesophageal reflux disease (GORD) nor with prescribing guidelines for PPIs, with significant financial costs to patients and PBS. This study encourages clinical discussion regarding quality use of these medicines. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density LossGastroenterology, 2010
- Cost Analysis of Long-Term Treatment of Patients with Symptomatic Gastroesophageal Reflux Disease (GERD) with Esomeprazole On-Demand Treatment or Esomeprazole Continuous Treatment: An Open, Randomized, Multicenter Study in Switzerland*Value in Health, 2009
- Clopidogrel, Genetics, and Drug ResponsivenessNew England Journal of Medicine, 2009
- The Australian rise of esomeprazole—was expenditure on samples a contributor?Pharmacoepidemiology and Drug Safety, 2008
- Overuse of proton pump inhibitorsJournal of Clinical Pharmacy and Therapeutics, 2008
- Overprescribing proton pump inhibitorsBMJ, 2008
- Proton pump inhibitor-responsive chronic cough without acid reflux: a case reportJournal of Medical Case Reports, 2007
- Proton-Pump Inhibitors and Hypomagnesemic HypoparathyroidismNew England Journal of Medicine, 2006
- Rebound acid hypersecretion after long‐term inhibition of gastric acid secretionAlimentary Pharmacology & Therapeutics, 2004
- Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methodsBMJ, 2001